Brought to you by 
The Medicines Co. buys Rempex for $140mm up front plus $334mm in potential earn-outs
27 Aug 2020
Executive Summary
The Medicines Co. (critical care products) paid $140mm in cash to acquire privately held Rempex Pharmaceuticals Inc., which is developing therapeutics aimed at antibiotic resistance. TMC also agreed to pay up to $214mm in earn-outs based on development and regulatory achievements, and $120mm in commercial milestones.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
The Medicines Co. buys Rempex for $140mm up front plus $334mm in potential earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice